The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.20 - Manufacture of pharmaceutical preparations
1,000 jobs Number of planned job creations
Announcement Date
4 March 2014
Employment effect (start)
1 April 2014
Foreseen end date
Description
The Danish based MNC in pharmaceutical products, Novo Nordisk, plans to create 1,000 new jobs during 2014 of which 300 will be production jobs. This was reported by the union of the potential new workers, United Federation of Danish Workers, 3F, on the 4 March 2014.
Around 100 of the new jobs will be at the production site in Kalundborg in West Zealand. Other jobs will be created in Copenhagen. Novo Nordisk mainly produces insulin and has 16,025 employees in Denmark as of March 2014.
The Novo Nordisk facility at Kalundborg is part of a well-known eco-industrial complex involving many other plants.
Sources
5 March 2014: Avisen
4 March 2014: 3F.DK
Citation
Eurofound (2014), Novo Nordisk, Business expansion in Denmark, factsheet number 76719, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/76719.